AR088398A1 - Preparacion de liberacion sostenida - Google Patents

Preparacion de liberacion sostenida

Info

Publication number
AR088398A1
AR088398A1 ARP120103908A ARP120103908A AR088398A1 AR 088398 A1 AR088398 A1 AR 088398A1 AR P120103908 A ARP120103908 A AR P120103908A AR P120103908 A ARP120103908 A AR P120103908A AR 088398 A1 AR088398 A1 AR 088398A1
Authority
AR
Argentina
Prior art keywords
sustained release
release preparation
hours
average
time point
Prior art date
Application number
ARP120103908A
Other languages
English (en)
Spanish (es)
Inventor
Tanoue Yutaka
Murakawa Yusuke
Mizuno Yumiko
Enoto Kaoru
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR088398A1 publication Critical patent/AR088398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP120103908A 2011-10-21 2012-10-19 Preparacion de liberacion sostenida AR088398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21

Publications (1)

Publication Number Publication Date
AR088398A1 true AR088398A1 (es) 2014-05-28

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103908A AR088398A1 (es) 2011-10-21 2012-10-19 Preparacion de liberacion sostenida

Country Status (30)

Country Link
US (1) US9907789B2 (enExample)
EP (1) EP2768487B1 (enExample)
JP (1) JP6093762B2 (enExample)
KR (1) KR20140081826A (enExample)
CN (1) CN104039313A (enExample)
AP (1) AP2014007645A0 (enExample)
AR (1) AR088398A1 (enExample)
AU (1) AU2012326976B2 (enExample)
BR (1) BR112014008744A2 (enExample)
CA (1) CA2852417A1 (enExample)
CL (1) CL2014000992A1 (enExample)
CO (1) CO6960544A2 (enExample)
CR (1) CR20140213A (enExample)
DO (1) DOP2014000077A (enExample)
EA (1) EA201490840A1 (enExample)
EC (1) ECSP14013328A (enExample)
IL (1) IL232114A0 (enExample)
IN (1) IN2014DN03169A (enExample)
MA (1) MA35717B1 (enExample)
MX (1) MX2014004679A (enExample)
NZ (1) NZ624275A (enExample)
PE (1) PE20141189A1 (enExample)
PH (1) PH12014500856A1 (enExample)
SG (2) SG10201700121YA (enExample)
TN (1) TN2014000152A1 (enExample)
TW (1) TW201323018A (enExample)
UA (1) UA113858C2 (enExample)
UY (1) UY34403A (enExample)
WO (1) WO2013058409A1 (enExample)
ZA (1) ZA201403103B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP7904682B2 (ja) * 2021-10-28 2026-08-13 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
KR100355130B1 (ko) 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
EP1413315A4 (en) 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (enExample) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
US20060280794A1 (en) 2003-06-06 2006-12-14 Naoru Hamaguchi Solid pharmaceutical preparation
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
MX2007002375A (es) 2004-08-31 2007-04-23 Pfizer Prod Inc Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad.
EA200800879A1 (ru) 2005-09-22 2008-10-30 ЭсБи ФАРМКО ПУЭРТО РИКО ИНК. Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007072992A2 (en) 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
CA2647982C (en) 2006-03-30 2014-06-10 Nippon Zoki Pharmaceutical Co., Ltd. Solid pharmaceutical preparation containing tramadol
WO2007126135A1 (en) 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl
CA2677623C (en) 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010039690A1 (en) 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
EP2486918A4 (en) 2009-10-09 2014-02-26 Yungjin Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) * 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
CN107362165A (zh) * 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
CO6960544A2 (es) 2014-05-30
JP2014530802A (ja) 2014-11-20
CR20140213A (es) 2014-06-18
PH12014500856A1 (en) 2014-05-19
JP6093762B2 (ja) 2017-03-08
MX2014004679A (es) 2014-08-01
EP2768487B1 (en) 2020-06-03
CN104039313A (zh) 2014-09-10
US9907789B2 (en) 2018-03-06
EP2768487A1 (en) 2014-08-27
MA35717B1 (fr) 2014-12-01
UA113858C2 (uk) 2017-03-27
KR20140081826A (ko) 2014-07-01
TN2014000152A1 (en) 2015-09-30
UY34403A (es) 2013-05-31
PE20141189A1 (es) 2014-09-24
WO2013058409A1 (en) 2013-04-25
IN2014DN03169A (enExample) 2015-05-22
AU2012326976A1 (en) 2014-05-29
SG10201700121YA (en) 2017-03-30
AU2012326976A2 (en) 2014-06-12
AU2012326976B2 (en) 2017-08-17
BR112014008744A2 (pt) 2017-04-18
DOP2014000077A (es) 2014-07-15
ECSP14013328A (es) 2014-05-31
IL232114A0 (en) 2014-06-30
ZA201403103B (en) 2015-08-26
CA2852417A1 (en) 2013-04-25
NZ624275A (en) 2016-09-30
SG2014012025A (en) 2014-06-27
TW201323018A (zh) 2013-06-16
AP2014007645A0 (en) 2014-05-31
CL2014000992A1 (es) 2014-09-05
US20140248362A1 (en) 2014-09-04
EA201490840A1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
ECSP14013328A (es) Preparacion de liberacion sostenida
MX2019003693A (es) Formulaciones de insulina de accion prolongada.
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
CL2011002194A1 (es) Formulacion que comprende anticuerpo en un regulador de histidina-arginina ph 4.5 a 6.5; articulo de manufactura que comprende dicha formulacion; metodo para estabilizar un anticuerpo en una formulacion farmaceutica acuosa.
CY1117419T1 (el) Εναιωρημα βλαστοκυτταρου
AR084285A1 (es) Composiciones inmunogenicas
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
CO6811816A2 (es) Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminiácidos no naturales
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
CL2015003352A1 (es) Composiciones antitranspirantes
MX358716B (es) Composiciones estables para el cuidado bucal que comprenden un aminoácido básico , una sal de estroncio y una fuente de ion fluoruro y usos de las mismas.
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
BR112015006868A8 (pt) Composições farmacêuticas antibióticas de tazobactam arginina, método para fazer e uso das mesmas
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
ECSP099066A (es) Vacuna combinada estreptococica
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
IN2015DN04074A (enExample)
EA201792122A1 (ru) Кристаллическое соединение как ингибитор фермента семикарбазидчувствительной аминоксидазы (ssao)
TR201005241A1 (tr) Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
UA117137C2 (uk) Глюкопіранозилзаміщені похідні індолсечовини і їх застосування як інгібіторів sglt
BR112017005618A2 (pt) ?sal de éster metílico de fenilglicina?.
MX392681B (es) Composiciones para el cuidado bucal
CO6670588A2 (es) Producto para el cuidado bucal y método de uso y elaboración del mismo
TR201107563A1 (tr) Vildagliptin ve gliklazid kombinasyon kompozisyonu.

Legal Events

Date Code Title Description
FB Suspension of granting procedure